Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time.
Bleeding and thrombosis are well known major causes of morbidity and mortality in patients with myeloproliferative disorders (MPD) but the relationship between these clinical events and the commonly found platelet function abnormalities have not been established. In this study we performed simultaneous laboratory evaluations in 54 patients with MPD to investigate abnormalities in platelet aggregation and cyclooxygenase activity, the latter by using an in vitro aspirin inhibition test; the studies were repeated in 22 patients 1-27 months later. We have found platelet hyper- and hypofunction co-existing in some patients (9/54), and change of platelet function during the course of the disease (7/22) with platelet hypofunction being the only constant abnormality over time. These results may explain the lack of correlation between the clinical events and the limited assessment of platelet function in the hitherto published studies, and also suggest the need for repeated evaluations to properly assess the relative risk for bleeding and thrombosis.
Baker
R I
RI
Department of Clinical Haematology, St. George Hospital, Sydney, Australia.
Manoharan
A
A
D000368:Aged; D001241:Aspirin / Q000494:pharmacology; D001791:Blood Platelet Disorders / Q000097:blood* / Q000150:complications / Q000473:pathology; D001792:Blood Platelets / Q000473:pathology / Q000502:physiology*; D005260:Female; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000097:blood / Q000150:complications; D006801:Humans; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000097:blood* / Q000150:complications / Q000473:pathology; D010974:Platelet Aggregation / Q000187:drug effects; D010976:Platelet Count; D012189:Retrospective Studies; D013927:Thrombosis / Q000097:blood / Q000150:complications
D001241:Aspirin